Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson's disease patients by Bedarf, J.R. et al.
RESEARCH Open Access
Functional implications of microbial and
viral gut metagenome changes in early
stage L-DOPA-naïve Parkinson’s disease
patients
J. R. Bedarf1,2†, F. Hildebrand4†, L. P. Coelho4, S. Sunagawa4,5, M. Bahram9,10, F. Goeser3,11, P. Bork4,6,7,8,13*
and U. Wüllner1,2,12*
Abstract
Background: Parkinson’s disease (PD) presently is conceptualized as a protein aggregation disease in which
pathology involves both the enteric and the central nervous system, possibly spreading from one to another via
the vagus nerves. As gastrointestinal dysfunction often precedes or parallels motor symptoms, the enteric system
with its vast diversity of microorganisms may be involved in PD pathogenesis. Alterations in the enteric microbial
taxonomic level of L-DOPA-naïve PD patients might also serve as a biomarker.
Methods: We performed metagenomic shotgun analyses and compared the fecal microbiomes of 31 early stage,
L-DOPA-naïve PD patients to 28 age-matched controls.
Results: We found increased Verrucomicrobiaceae (Akkermansia muciniphila) and unclassified Firmicutes, whereas
Prevotellaceae (Prevotella copri) and Erysipelotrichaceae (Eubacterium biforme) were markedly lowered in PD
samples. The observed differences could reliably separate PD from control with a ROC-AUC of 0.84. Functional
analyses of the metagenomes revealed differences in microbiota metabolism in PD involving the ẞ-glucuronate
and tryptophan metabolism. While the abundances of prophages and plasmids did not differ between PD and
controls, total virus abundance was decreased in PD participants. Based on our analyses, the intake of either a MAO
inhibitor, amantadine, or a dopamine agonist (which in summary relates to 90% of PD patients) had no overall
influence on taxa abundance or microbial functions.
Conclusions: Our data revealed differences of colonic microbiota and of microbiota metabolism between PD
patients and controls at an unprecedented detail not achievable through 16S sequencing. The findings point to a
yet unappreciated aspect of PD, possibly involving the intestinal barrier function and immune function in PD
patients. The influence of the parkinsonian medication should be further investigated in the future in larger cohorts.
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Background
Idiopathic Parkinson’s disease (PD) disease is conceptual-
ized as a progressive protein aggregation disease with the
formation of neuronal cytoplasmic aggregates of mis-
folded α-synuclein (α-syn) and other proteins as the
neuropathological hallmark (Lewy bodies [LB]) [1]. LB are
present not only in the central nervous system (CNS) but
also in the enteric nervous system (ENS) of the entire
gastrointestinal tract, corresponding to the clinical notion
that the gastrointestinal tract is involved in PD [2].
Lewy, in his original thesis work in 1913, already identi-
fied the dorsal motor nucleus of the vagus as a hotspot of
brain pathology and Braak et al. more recently confirmed
the early involvement of the vagus and hypothesized that
PD might originate in the gut and that α-syn aggregation
might spread via vagal structures into the CNS and higher
cortical regions [3]. The importance of the vagus for partly
bi-directional interactions of the ENS and the CNS (“gut-
brain axis”) [4–6] has become even more evident since the
identification of the cholinergic anti-inflammatory pathway
[7]. In line with this direct connection of gut and brain neu-
rons, increasing evidence from cell culture and animal ex-
periments seems to support the hypothesis of spreading or
seeding of α-syn oligomers [8, 9]. The deposition of α-syn
within the colon can help to distinguish PD patients from
controls [10–13]. Nevertheless, when assessed with conven-
tional immunohistochemistry, its diagnostic value as a bio-
marker has not been finally confirmed as α-syn staining in
colonic mucosa was likewise found in PD patients and con-
trols [14], which not necessarily refutes the concept of an
intestinal origin of PD pathogenesis. Thus, additional yet
unidentified factors beyond α-syn must be involved in the
presumed PD disease process.
The gastrointestinal microbiome encompasses a vast di-
versity of bacterial species and may be regarded as an
extracorporeal organ system, which interacts with its host
in unprecedented ways just being unraveled now [15]. Se-
verely disturbed gut homeostasis is detrimental for the
host but the effects of smaller changes or differences in
species variation for nutrition [16, 17], behavior [18], and
drug metabolism [19] are just beginning to emerge. Re-
cent studies already linked an altered microbiome to PD,
but most participants were well advanced and treated with
L-DOPA [20–22], which affects colonic motility and may
promote intestinal bacterial overgrowth [23].
Using metagenomic shotgun analysis, we found that
early, L-DOPA-naïve PD patients carry an altered gut
microbiota composition, i.e. specific taxonomic groups,
among others related to intestinal barrier and immune
functions, were overrepresented or underrepresented.
Functional analyses also suggested differences in micro-
biota ẞ-glucuronate and tryptophan degrading pathways.
Moreover, total virus abundance was decreased in PD
participants.
Methods
Study participants and clinical characteristics
This study was approved by the local ethics committee of
the University of Bonn and all participants gave informed
consent (internal ethics vote 126/02). Study participants
were recruited from the Department of Neurology at the
University of Bonn. To reduce any potential gender ef-
fects, we included only male participants in the study.
Thirty-one male PD patients (diagnosed according to the
UK Brain Bank criteria [24]) were compared to 28 male
age-matched non-parkinsonian controls.
Disease severity was measured using the Unified PD Dis-
ease Rating Scale (UPDRS part III). Gastrointestinal symp-
toms and presence of constipation were assessed with a
modified version of an interview-based Gastrointestinal
Symptom Rating Scale (GSRS) (selected items: borboryg-
mus, abdominal distension, increased flatus, decreased pas-
sage of stools, increased passage of stools, loose stools, hard
stools, urgent need for defecation and feeling of incomplete
evacuation, each item was rated 0–3 according to intensity,
frequency, duration or social impact depending on the re-
spective item, Additional file 1) [25]. To avoid alterations of
gut microbiota related to either gastrointestinal dysfunction
of late stage PD or L-DOPA-induced intestinal effects, we
included only early stage PD participants (onset of motor
symptoms and diagnosis of PD within the past year) who
were naïve to L-DOPA therapy. Further exclusion criteria
were: (1) chronic and inflammatory gastrointestinal diseases
including chronic constipation; (2) the use of laxatives or
immunosuppressive agents in the past three months; (3)
atypical or secondary parkinsonism; while (4) the use of an-
tibiotics in the past three months in principle was an exclu-
sion criterion; however, we included three PD patients and
three controls despite the intake of antibiotics for one to
three days in a period of 28–34 days prior to feces sampling
as the omission of those cases from the analyses did not
change any result (see also Additional file 2).
Controls were matched regarding general demographics
(Table 1, general demographics). Gastrointestinal symp-
toms were comparable in both groups; in particular, no
relevant constipation was present in PD participants; diet-
ary and smoking habits did not differ between groups. No
detailed dietary plan was requested prior to the feces col-
lection and samples were collected as first bowel move-
ment of the day.
Analysis of microbiota
Non-invasively obtained stool samples were shotgun se-
quenced (paired end) using an Illumina Hiseq4000 and fur-
ther analyzed with the MOCAT2 pipeline [26]. Briefly,
taxonomic mapping quality-controlled generated profiles
reads (minimum length cutoff 45 bp, minimum quality
score cutoff 20, reads matching Illumina adapters, or hu-
man genome were removed) to a database of ten universal
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single-copy marker genes that were extracted from 3496
NCBI reference genomes and 263 human gut metagen-
omes [27]. For abundance estimates at the species level, we
used mOTU (molecular operational taxonomic units)
abundances [27] and for genus-level and family-level abun-
dances, individual NCBI taxonomy-annotated marker gene
abundances were summed up.
Quality-controlled reads were also mapped against an an-
notated reference gene catalog for the human gut micro-
biome. On average, 88% of all reads could be mapped to
the reference gene catalogue (Additional file 3). Abun-
dances of individual genes summed up according to their
KO annotation in the KEGG (Kyoto Encyclopedia of Genes
and Genomes) database. KEGG and GMM (Gut specific
Metabolic Modules) pathway [28] abundances were esti-
mated with the same algorithm as in [29], re-implemented
in C++, available from github.com/hildebra/Rarefaction.
Briefly, we estimated for each metabolic pathway which of
several alternatives had the highest coverage given our KO
abundance matrix. If the coverage per pathway was higher
than 30%, the median abundance of all KOs in this pathway
was used to estimate pathway abundance.
To estimate the number of phages and viruses, we
choose a reference gene catalog independent approach,
as assembly of mobile genetic elements is notoriously
error prone and imprecise. MOCAT2 quality filtered
reads were mapped against the ACLAME [30] database
using Diamond [31] in sensitive mode, after format con-
version from fastq to fasta using sdm [32]. Reads map-
ping with an e-value <1e-7 were considered valid hits
against the database and the number of reads mapping
to the classes of “Plasmid,” “Prophage,” and “Virus” were
counted and normalized by read number.
Statistical methods
Statistical analysis was conducted in R 3.0.0. For all
univariate tests, taxa with less than five reads over all
samples were excluded from this analysis to avoid arti-
facts, similar to the approach in [33]. The matrix was
normalized dividing each feature by the respective total
sample sum and transformed with log10(x + 1), where x
is the normalized feature coverage as calculated in the
mOTUs algorithm. For species and mOTU level
analysis, we made the filtering options more explicit to
exclude spurious correlations: from the abundance
matrix features were removed that were absent in more
than ten samples, had less than ten accumulated or two
mean read coverage. Sample count matrices were rar-
efied using the R implementation of the rtk toolkit [34].
Significance between groups of samples was tested with
a Kruskal–Wallis test, as implemented in R. The ordina-
tions (non-metric multidimensional [NMDS] ordination)
and subsequent statistical analysis were calculated using
the R-package vegan with Bray-Curtis distance on the
rarefied and log-transformed taxa abundance and visual-
ized with custom R scripts. Intergroup differences for
the microbiota were calculated using a PERMANOVA
test as implemented in vegan [35]. This test compares
the intragroup distances to the intergroup distances in a
permutation scheme and thus calculates a P value. For
all PERMANOVA tests we used 4999 randomizations.
PERMANOVA post hoc P values were corrected for
multiple testing using the Benjamini–Hochberg false dis-
covery rate (q-value) [36]. Sample composition plots
were visualized with custom R scripts (available from
github.com/hildebra/PD_helpers_R).
Univariate testing
Univariate testing for differential abundances of each
taxonomic unit between two or more groups was tested
using a Kruskal–Wallis test (P value), corrected for
multiple testing using the Benjamini–Hochberg false dis-
covery rate (q-value).
Table 1 Clinical characteristics and general demographic
parameters of study participants
PD Control P value
Demographics
n 31 28
Age (years, mean ± SD) 64.8 ± 9.5 65.6 ± 10.4 0.970
Clinical data
UPDRS III (mean ± SD) 12.6 ± 6.9 0 ± 0 <0.001
GIT symptoms incl. constipation
(GSRS, mean ± SD)
3.4 ± 2.9 2.2 ± 2.0 0.172
Total serum bilirubin 0.23 ± 0.03 0.23 ± 0.03 0.593
Nutritional habits
Diet
Omnivorous 30 [96.8%] 28 [100%]
Vegetarian 1 [3.2%] 0 [0%]
Probiotics 4 [12.9%] 1 [3.6%]
Medication
Amantadine 26 [83.9%] 0 [0%]
Dopamine agonist 11 [35.5%] 0 [0%]
MAO inhibitor 28 [90.3%] 0 [0%]
L-DOPA 0 [0%] 0 [0%]
Statin intake 1 [3.2%] 11 [39.3%]
Metformin 1 [3.2%] 3 [10.7%]
Acetylsalicylic acid 2 [6.5%] 7 [25.0%]
Smoking
No 10 [32.3%] 9 [32.1%]
Yes 5 [16.1%] 4 [14.3%]
Ex-smoker 15 [48.4%] 15 [53.6%]
UPDRS Unified Parkinson’s Disease Rating Scale, GIT gastrointestinal, GSRS
Gastrointestinal Symptoms Rating Scale, MAO monoamine oxidase,
L-DOPA Levodopa
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The Blocked “independence test” function calls (with
the following options: “ytrafo = rank, teststat = scalar” for
blocked WRST) were used from the COIN R package
[37] to control for potential confounders, such as the in-
take of a statin.
Post hoc statistical testing for significant differences be-
tween all combinations of two groups was conducted only
for taxa with a significance of P < 0.2. Wilcoxon rank-sum
tests were calculated for all possible group combinations
and corrected for multiple testing using Benjamini–Hoch-
berg false discovery rate (q-value). GSRS, UPDRS III, and
Bilirubin correlations to taxa were tested using a spear-
man correlation test; P values were corrected using Benja-
mini–Hochberg false discovery rate.
Further, we confirmed these results using ANCOM
[38], a statistical test developed for microbial count data,
using an R implementation version 1.1-3 and the add-
itional parameters multcorr = 2 and sig = 0.1, that is with
multiple testing correction at significance 0.1.
Classifier
For generating a classifier, genera were filtered, removing
any whose mean relative abundance across samples was
below 0.1%. Subsequently, relative abundances were nor-
malized by a log-transformation with a pseudo-count
equal to one-tenth of the estimated detection limit, esti-
mated as the minimal abundance of any positively de-
tected taxa [39]. Fitting a classifier proceeds in two steps.
First, a lasso-penalized logistic regression classifier is used
to select the top features (the features with the highest ab-
solute weight are selected, Additional file 4). Second, these
features are used in an unpenalized logistic regression
classifier. Classifiers were based on the scikit-learn imple-
mentation [40]. The classifier was generated using cross-
validation in a leave-one-out schedule (feature selection
was performed de novo at each iteration to provide un-
biased estimates). Relevant taxa were extracted from a
model trained on the whole data. P values were computed
by the Mann–Whitney test on the prediction scores of the
two classes (PD and control). Classifier performance was
reported as ROC-AUC, representing the probability that
the classifier will correctly label a new sample.
Structural equation model (SEM) from the same sample
distribution
SEMs were used to test causality through examination
of both direct and indirect effects of bacteria and medi-
cation on PD and vice versa [41]. We also evaluated an
alternative model in which medication affects bacteria
and bacteria in turn affect the disease. Based on this we
used an exploratory approach to approximate a signifi-
cant model fit. Briefly, non-significant variables and
paths were subsequently removed using backward elim-
ination stepwise regression and new paths were added
based on modification indices until significant model fit
was achieved (Additional file 5). This analysis was per-
formed using the computer program AMOS ver. 7.0
(SPSS, Chicago, IL, USA).
Results
Microbiota in PD
Analyzing the two sample sets for differences in their bac-
terial composition we detected significant differences be-
tween PD and control samples (Permanova test, P < 0.001,
Additional file 6).
A NMDS ordination separated PD and controls on the
first axis of microbiota composition using Bray–Curtis dis-
tance, which explained 49.32% of variation, while axes 2
and 3 did not show this separation (Fig. 1a). The compos-
ition of PD patient gut microbiota was significantly differ-
ent from control at all taxonomic levels, while there was
little variation within PD and the control group. Richness
(i.e. number of taxa present in a sample) between commu-
nities was not significantly different, whether samples were
pooled or considered as single samples (Additional file 7).
Key taxonomic differences in the PD gut microbiota
In general, we observed Clostridiales, Bacteroidaceae, and
Ruminococcaceae as the most abundant families in both
sample sets accounting for 50–52% of the relative family
abundance. Univariate tests revealed significant changes in
family as well as in genus abundance in PD samples
(Additional file 8). Verrucomicrobiaceae (genus Akkerman-
sia), unclassified Bacteria (of the classified prokaryotes) and
Firmicutes were increased, whereas Prevotellaceae (genus
Prevotella) and Erysipelotrichaceae (genus Eubacterium)
were markedly lowered in PD samples (Fig. 1b, Additional
file 9a, and b; P < 0.05, q < 0.1; with the exception of Prevo-
tella (genus) with a P < 0.05 and a q = 0.13, thus being n. s.).
Using ANCOM, we similarly found genera Akkermansia,
Prevotella, Eubacterium, unknown Bacteria, and unknown
Firmicutes to be significantly different between PD and
control patients.
Metagenomics provides species resolution. Among the
classified bacteria, we thus identified a pattern of signifi-
cantly increased key species in PD including Akkerman-
sia muciniphila and Alistipes shahii. On the other hand,
Prevotella copri, Eubacterium biforme, and Clostridium
saccharolyticum were decreased (Fig. 1b and c).
Correlation of microbiota with PD clinical scores
No significant taxonomic associations were detected, nei-
ther at genus nor at species level, when microbiota abun-
dance was correlated with clinical data (UPDRS III, GSRS,
or total serum bilirubin, despite of the presumed decreased
ẞ-glucuronidation in PD participants, Additional file 10).
This was expected, as we had aimed to recruit a cohort of
PD patients with a short duration of (motor) symptoms
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and subjective impairment; nevertheless, some interesting
trends (q > 0.1) were observed regarding the symptom
severity of PD (UPDRS III) for three different Eubacteria
(E. eligens, E. rectale, and E. hallii, Fig. 1d).
Both parkinsonian and gastrointestinal symptoms severity
including constipation were rather low in our sample set of
early L-DOPA-naïve patients and, except for core parkin-
sonian features, did not differ from controls (Table 1). We
could not detect any deviations pointing to a possible
confounder.
Functional analysis of the PD microbiome
In order to explore differences in the metabolic potential of
gut microbiota between PD and control patients, we further
estimated the abundance of metabolic pathways, using our
metagenomic reads mapped to functional orthologues from
the KEGG and GMM databases (Additional file 11).
We identified a significantly decreased gene abundance
for D-Glucuronate degradation in PD participants com-
pared to controls (System: D-Glucuronate degradation, D-
glucuronate→ pyruvate and D-glyceraldehyde 3P, Fig. 2a
and b, KEGG module number M00061, P < 0.05, q < 0.1).
GMM Orthology corroborated a decreased abundance of
genes in the pathway of beta-D-glucuronide and D-
glucuronate degradation in PD participants (Fig. 2a and b,
GMM module number MF0091, P < 0.05, q < 0.1). This was
paralleled by a decrease in genes for 5-dehydro-4-deoxy-D-
glucuronate degradation (Fig. 2a and b, GMM module
number MF0065, P < 0.05, q = 0.11).
Interestingly, we also found two different pathways for
tryptophan metabolism, which appeared to be more active
in the microbiota of PD participants (tryptophan→ kynur-
enine→ 2-aminomuconate, KEGG module number
M00038, Fig. 2a and b; tryptophan degradation, MF0009
(GMM module number), Fig. 2a and b, increased formate
conversion, GMM module number MF0118, Fig. 2a and
b). Although a lack of tryptophan and serotonin is a hall-
mark of PD, this finding did not reach statistical signifi-
cance after multiple testing correction (all p < 0.05, q > 0.1)
and needs further exploration in a larger cohort.
To determine which bacteria are involved in these path-
ways, we traced the contributing genes and determined
their likely taxonomic origin (Fig. 2a and b). Although mul-
tiple genera contribute to all modules, only in modules
MF0065 and MF0118 could we find evidence of any genera
contributing significantly more reads in PD patients than
a
b
c
d
Fig. 1 Genus and species level differences in PD participants and controls. a NMDS ordination of all samples used in this study, using a Bray–Curtis
between-sample distance at genus level. This shows the composition relatedness of samples and that PD samples form a subgroup. Outliers denoted with
# took antibiotics in a period of 28–34 days prior to feces sampling. See also Additional file 2 for taxonomic analysis while taking these samples into
account. b Genus-level sample composition. c The most significant species or groups of taxa that could not be further classified. Unclassified Prevotella is
not significant after multiple testing, but was implied in PD in several studies (see “Discussion”). d Species correlating strongest to PD disease severity (as
measured by UPDRS III). Note that after multiple testing correction, these are all q > 0.1
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control patients, after multiple testing correction (Fig. 2c).
In both cases this was Eubacterium.
Influence of medication on the microbiota
Given the important influence of pharmaceuticals on the
gut microbiota [42], we tested the effects of the
concomitant PD-specific medication in our cohort
(Additional file 12). No significant differences in taxa
abundances (families, genera, species) were apparent in
the relatively small samples grouped according to the vari-
ous combinations of anti-PD medication (dopamine agon-
ist +MAO inhibitor + amantadine: n = 10, MAO inhibitor
Tryptophan pathway c Glucuronate pathway 
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Fig. 2 Functional differences in PD patients based on selected metabolic pathways. a Phylum and (b) genus level composition of six modules that
were increased/decreased in PD patients. c All genera were contributing to these modules as expected by random chance, with the exception of
MF0065 and MF0118, where a higher than expected proportion of reads contributing could be traced to Eubacterium in PD patients
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+ amantadine: n = 14, MAO inhibitor: n = 3, no therapy: n
= 3; there was only one patient with dopamine agonist +
MAO inhibitor, who was not included). However, patients
treated with MAO inhibitors in combination with amanta-
dine (n = 14, i.e. 45.2% of the PD participants) displayed a
significantly increased richness (Additional file 12d), which
did not affect the overall richness of the entire PD cohort.
Among the concomitant drugs the intake of a statin
showed an influence on the gut microbiota. We identified
five families significantly different between statin-treated
and untreated patients (Burkholderiaceae, Propionibacter-
iaceae, Enterococcaceae, Actinomycetaceae, and Entero-
bacteriaceae), none of which contributed to the
differences observed between PD participants and con-
trols (Additional files 12a, c and 13).
Virus abundance is lowered in PD participants
We tested the fraction of the reads that could be mapped
to the ACLAME database to estimate the amount of mo-
bile elements in the metagenomes, though this method is
limited to known diversity of mobile elements. While the
abundances for prophages and plasmids were not different
between PD and controls, total virus abundance (reflecting
bacterial and archaeal phages) was decreased in PD partici-
pants (P = 6.7e-5, Additional file 14a). We also found that
viruses were increased in participants treated with a statin
(P = 0.0002), and therefore tested for differences between
PD participants and controls, corrected for statin treatment.
This again showed a decrease of the virus load in PD par-
ticipants (P = 0.0009, Additional file 14b).
Gut microbes discriminate PD participants from controls
Using a logistic regression classifier to select predictive
features, we could discriminate PD from control with a
cross-validated AUC of 0.84 using six different taxa (Eubac-
terium, Capnocytophaga, Phascolarctobacterium, Akker-
mansia, and mOTUs no further classified than to
Firmicutes as well as Bacteria level); this corresponds to a
sensitivity of 64.5% and a specificity of 89.2% (P value =
4.19 × 10−6; Fig. 3, see also Additional files 4 and 15). Eu-
bacterium was frequently selected as most important genus,
singularly predicting PD with an AUC of 0.63 (sensitivity =
74.2%, specificity = 57.1%, P value = 0.047). The addition of
constipation scores as a putative predictive feature showed
no added predictive value over the six taxa used, contrary
to prior studies [20].
Structural equation model
Using a SEM (see “Methods”), we summarized the ob-
served differences in key taxa abundances, metadata, and
functional pathways in a holistic statistical model of the PD
gut microbiota (Fig. 4). Compared with the LASSO regres-
sion classifier mentioned above, this modeling approach en-
ables causality inference through testing both direct and
indirect correlations between biotic factors (e.g. bacterial
abundance and metadata, e.g. medication), until the model
reaches a significant fit through optimization of the correl-
ation network. The best-fit SEM supported our hypothesis
that medication used for the studied patients has no direct
effect on bacteria, explaining 87% of variation. This model
indicated that differences in taxa abundances and also func-
tional changes in ẞ-glucuronidation are basically driven by
PD and not vice versa with an Akaike information criterion
Fig. 3 Classification of PD participants based on their microbiome. Here
the classifier selected a very similar set of features as were determined by
univariate testing (Fig. 1). With only six genera, PD could be separated
from control patients with an AUC of 0.84. The exact mOTU composition
of each feature is given in Additional file 15
Fig. 4 Structural equation modeling (SEM). SEM analysis of PD in relation
to key correlating bacterial functions and taxa (MSEA= 0, PCLOSE = 0.79,
AIC = 59.385). Values on paths and boxes are standardized regression and
determination coefficients (R2), respectively. Dashed lines and red colors
denote negative relationships. The thickness of lines is proportional to
regression coefficients. All relationships are statistically significant (P< 0.05,
Additional file 5). AIC Akaike information criterion, MSEA mean square
error of approximation, PCLOSE probability of close fit
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(AIC) of 59.4 (Additional file 4), while the alternate model
(PD is partly driven by biotic factors) had an AIC of 67.5
(Additional file 16). None of the taxa seems to influence
the PD microbiota. However, in this model the PD micro-
biota could be influenced by the intake of a MAO inhibitor
(that was only taken by a fraction of participants). Key taxa
in this model reflect changes on species levels. Among taxa
themselves, the strongest positive correlation was found for
Eubacterium and unclassified Firmicutes, when correcting
for cross interactions.
Discussion
Main results
Our results show a significantly altered microbial compos-
ition in early disease stage L-DOPA-naïve PD participants.
Compared to earlier studies investigating microbiota in PD
patients using 16S-based techniques the chosen methods
allowed to detect changes at the species level and also a de-
creased virus load in PD.
We confirmed a decrease of Prevotella copri in PD
and in addition found decreased Eubacterium biforme
and Clostridium saccharolyticum and increased Akker-
mansia muciniphila as well as Alistipes shahii. Based on
the taxonomic differences alone, logistic regression after
feature selection allowed separation of PD patients in
early stages from controls with good accuracy (AUC
0.84). Furthermore, our analyses point to differences in
microbiota metabolism, namely in ẞ-glucuronate and
tryptophan degrading pathways.
Taxa abundances
Despite several differences in study design compared to
previous work [20, 21], our results strengthen the hy-
pothesis of a PD-specific “microbial footprint.” The ob-
served differences though are not directly comparable,
since the previous studies were using 16S amplicon se-
quencing with its various biases [43], while we used
metagenomics with increased precision due to usage of
single copy marker genes with high confidence taxo-
nomic assignments [27]. Testing for causality inference
of biotic and abiotic factors seem to indicate that these
taxonomic changes are a consequence of the disease.
However, whether the observed changes are primary
changes or rather secondary, resulting from unidentified
effects, and whether it is either beneficial or harmful
cannot be decided at present.
The increase in Akkermansia muciniphila, which appears
to be in certain consistency in regards to the findings of
Keshavarzian et al., Scheperjans et al., and Unger et al.
[20–22], may illustrate this dilemma: it is a common mucin
degrader which has been shown to reverse diet induced
pathological intestinal changes in high-fat fed mice by re-
storing the intestinal mucus layer and the underlying epi-
thelium, thus being able to improve gut barrier function
[44, 45]. Protective effects of extracellular vesicles derived
from Akkermansia muciniphila on experimentally induced
colitis further support a beneficial influence on intestinal
immunity [46]. On the other hand, inflammatory and regu-
latory properties have been reported for Akkermansia,
probably mediated due to an increased exposure of im-
mune cells to microbial antigens upon breaking down the
mucosal mucin layer [47]. Preliminary evidence also linked
Akkermansia to multiple sclerosis [48]. Previous studies on
colonic biopsies and feces samples from treated and drug-
naïve PD participants suggested an altered mucosal barrier
function and PD patients exhibited significantly greater
intestinal permeability than controls, paralleled by an in-
creased mucosal staining for E. coli and α-syn [49]. Pro-
inflammatory dysbiosis may even trigger α-syn misfolding
or neuronal injury from gut-derived endotoxins [21, 50].
Although we did not identify E. coli species associated with
PD in our samples, the increase in Akkermansia might be
associated with a yet unexplored disease related impact on
mucosal barrier function.
Extending the results of Scheperjans et al. and Unger et
al. [20, 22], which pointed to a relatively lower abundance
of Prevotellaceae in advanced PD, Prevotella copri was
markedly lowered in our samples of early stage PD. On the
other side, Keshavarzian et al. [21] did not show this differ-
ence for fecal samples, albeit the trend was the same for
mucosal-derived PD samples. However, Prevotella abun-
dance was also reduced in Japanese multiple sclerosis pa-
tients and in autistic children, somewhat questioning the
specificity of this finding [51, 52]. The Prevotella enterotype
is the least prevalent in human individuals [53] and is re-
lated to dietary/fiber intake [54, 55]. In particular, Prevotella
enrichment has been linked to non-Western and/or fiber-
rich diets [56, 57]. Fibers are the primary substrate for short
chain fatty acids (SCFAs) including butyrate and reductions
in the latter can disrupt barrier function and promote in-
flammation [58]. The fact that, in various autoimmune dis-
eases including type 1/2 diabetes, irritable bowel disease,
rheumatoid arthritis, and Behcet’s disease reduced levels of
Prevotella have been found [42, 59–61], could indicate a de-
creased SCFA production (i.e. propionate) and in turn favor
inflammatory conditions in PD [21].
In contrast to Scheperjans et al. [16], we did not find in-
creased Ruminococcaceae (phylum Firmicutes) to compen-
sate lower levels of Prevotella but instead an increase in
unclassified Firmicutes. Interestingly, although the early, L-
DOPA-naïve PD patients hold a different species pattern
not yet affected by drug effects and the chronic constipa-
tion typically observed in late-stage PD, we found a certain
consistency with the advanced PD patients’ pattern.
Taken together, the observed bacterial pattern in our PD
samples might hint towards yet unexplored mechanisms of
a disturbed intestinal and immune function in PD patho-
genesis. Colonic biopsies from PD patients indeed showed
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enhanced pro-inflammatory cytokines and glial markers
correlating with disease progression [62, 63]. Furthermore,
there is evidence of α-syn contributing to neuro-
inflammation by potentiating microglial or astroglial
activation [64]. In line with this, recent work highlighted
the crucial role of microbiota on maturation and activity of
microglia [65], which have been considered as one of the
earliest contributors of neurodegeneration [66] and further
supports the importance of microbial-derived mediators
(gut peptides, chemokines, SCFAs) on immune regulation
and CNS function [65, 67].
A possible role for SCFAs in PD
SCFAs are essential energy sources for colonocytes and
reduced levels of SCFAs might not only contribute to a de-
creased colonic motility (i.e. constipation) but also led to an
increase in intestinal barrier leakiness [68–70]. Keshavar-
zian et al. and Unger et al. both suggested a beneficial role
for SCFAs as PD-derived feces were shown to contain less
SCFA butyrate-producing bacteria, including Blautia, Rose-
buria, and Coprococcus [21] as well as Faecalibacterium
prausnitzii [21, 22], which were previously attributed to
exert putative anti-inflammatory effects.
While SCFA administration contra-intuitively promoted
motor dysfunction and α-syn-mediated neuro-inflammation
in a germ-free transgenic mouse model over-expressing α-
syn, oral administration of heat killed bacteria had no effect
on motor performance, indicating the putative importance
for metabolically active microbiota in disease pathogenesis
[71]. Namely, when PD-derived microbiota (of treatment-
naïve new onset PD donors) were orally transferred to
germ-free mice, several taxa, including Roseburia, Rikenella-
ceae, and Enterococcus, were markedly altered in the
microbial profile of the recipient mice independently of its
genotype as when they received microbiota derived from
healthy donors.
While inconclusive at the moment, prospective research
on SFCA gene expression and metabolomic profiles of
microbiota in health and disease will shed further light on
this aspect.
Viral analyses
The gut bacteria harbor a diverse phageome and virome
that may contribute to function and structure of the
microbiome, but evidence from comparative analyses of
the human gut phageome is limited. Recently a compre-
hensive metagenomic analysis in 64 individuals sug-
gested a core phageome that was shared among more
than one-half of all individuals and might also exert
beneficial properties as it was reduced in individuals
with inflammatory bowel disease [72]. However, based
on our analysis, we could not find any differences in the
abundance of prophages and plasmids between PD and
control samples. In contrast, total virus amount was sig-
nificantly lowered in PD participants.
Importantly, the assessment of virus and phage load is
entirely dependent on the corresponding protein families
being present in the ACLAME database; therefore, we
only detect those phages or viruses, of which a closely
related reference genome is present in the database.
Testing for correlations between bacterial family and
viral load abundance showed no significant correlations
after multiple testing.
As viruses interact with host cells and influence immune
response (i.e. prevent inflammatory conditions [73]), there
might be various possibilities in which viruses interact in
the pathogenesis of PD. Although inconclusive at the mo-
ment, exploration of the specific role of viruses in PD is a
promising avenue to follow-up with more specific
research.
Functional aspect
Accumulating evidence suggests a direct impact of meta-
bolic alterations in microbiota on human health [74, 75].
We observed a putative reduction in microbiota ẞ-glucu-
ronidase activity in early stage PD participants. Decreased
ẞ-glucuronidation in the microbiota could imply a deteri-
oration of resistance to various pathogenic organisms [76].
Also, microbial derived ẞ-glucuronidases affect effective
dose availability of administered drugs by reactivation in
the gut, which has been shown for irinotecan therapy in
colorectal cancer patients [77]. Altered metabolisms of xe-
nobiotics or parkinsonian pharmaceuticals metabolized in
the ẞ-glucuronate degrading pathway must be determined
experimentally [78].
Our data further revealed a trend towards an increased
tryptophan degradation gene copy number in PD. If one as-
sumes that this increased genetic potential translates into
an increased tryptophan metabolization, this finding is in
line with previous research and is of particular interest as
L-tryptophan, the precursor for serotonin, is decreased in
PD patients’ brains. L-tryptophan is also metabolized to
kynurenines, whereof metabolites have regulatory immune
function and were described as either harmful or beneficial
in PD [79–81]. Urinary metabolomics profiling demon-
strated significant changes of urinary markers including an
increased tryptophan metabolism, which was associated
with the progression of PD [82]. Interestingly, catabolism of
serotonin also includes glucuronidation in the human
intestine [83].
The association with these metabolic pathways point to a
deeper involvement of Eubacteria with PD. Indeed Eubac-
teria spp. were decreased in PD (Eubacterium biforme) and
other Eubacteria species (E. hallii, E. rectale, E. eligens)
showed a trend towards correlation with disease severity
(n.s.). Specifically colonizing the mucus layer, particularly
Eubacterium rectale, might be interconnected with
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processes directly affecting the mucus layer due to its abil-
ity to gain access via flagella [84]. Further, diversity of Eu-
bacterium rectale was also reduced in an in vitro dynamic
gut model (M-SHIME) of long-term colonization of the
mucin layer when microbiota were derived from ulcerative
colitis patients [85]. Additionally, Eubacterium halii is
viewed as a key species impacting the microbial balance
due to its ability to produce several SCFAs [86]. In turn, al-
terations in the abundance of different Eubaceria might
contribute to the PD pathogenesis via metabolic but also
direct mucosal pathways.
Lowered Eubacteria (family Erysipelotrichaceae) in
mucosal as well as in fecal PD samples were similarly
observed in the study of Keshavarzian et al. [21]; how-
ever, a correlation with disease severity was not proven.
Clinical aspects
Instead, Keshavarzian et al. found PD duration correlating
with the greatest number of taxa, whereby the family
Lachnospiraceae, which includes several (supposedly anti-
inflammatory) butyrate producing bacteria, displayed a
significant negative correlation. Scheperjans et al. further
showed a significant association of Enterobacteriaceae
with the postural instability and gait disorder (PIGD) PD
phenotype [20], which was not confirmed in the work of
Unger et al. [22].
Namely, based on our analyses, the intake of different
anti-parkinsonian drugs had no overall influence on taxa
abundance or microbial functions. However, in future sub-
group analyses PD patients under the therapy with MAO-
inhibitors and amantadine might be favorably influenced
by an increased richness if assessed in a lager cohort. In
this context, it is worth noting another study, which was
published during the revision process of this manuscript
and which demonstrates instead independent effects of
different PD medications on the microbiome [87].
However, although the intake of a statin showed an in-
fluence on the gut microbiota with, in total, five families
being different in statin-treated individuals, none of
them contributed to the differences observed between
PD participants and controls when controlling for statin
intake with differential statistical methods. One caveat of
testing for confounders in our cohort is that this result
might be limited by the sample size being too small to
find even small effects, which is an unavoidable inherent
aspect of human cohort studies. However, future studies
should address this aspect.
Conclusions
Our data revealed differences of colonic microbiota be-
tween PD patients and controls at an unprecedented detail
not achievable through 16S sequencing: altered representa-
tion of several taxa including Eubacterium biforme, which
has not been reported previously and might be limited to
detection via metagenomics. The functional differences in
the gut microbiota included ẞ-glucuronate and tryptophan
degrading pathways. The findings point to a yet-
unappreciated aspect of PD, possibly involving the intestinal
barrier function and immune function in PD patients. We
further show the benefits of integrating functional micro-
biota predictions into microbial-based profiles to discrimin-
ate health and disease that is promising as it holds the
potential to identify PD patients. Furthermore, it is now evi-
dent that exploration of the PD virus populations is a
promising avenue to follow up with more specific research.
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